Erick Wayne DeVinney - 16 Mar 2026 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: Chief Innovation Officer
Issuer ticker: AXGN
Reported as of: 16 Mar 2026
Net transaction value: -$171,458
SEC form: 4
Accepted by SEC: 18 Mar 2026, 16:11:17 UTC
Prior SEC filing: 02 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Began, as attorney-in-fact for Erick DeVinney

Key filing fact

Erick Wayne DeVinney filed Form 4 for Axogen, Inc. (AXGN) on 18 Mar 2026.

Key facts

This page summarizes Erick Wayne DeVinney's Form 4 filing for Axogen, Inc. (AXGN).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 16:11.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: -$171,458.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001595972 Primary reporting owner

DeVinney Erick Wayne

Relationship: Chief Innovation Officer
Address: 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA
Signature: /s/ Marc Began, as attorney-in-fact for Erick DeVinney
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +6,363
Change %: +2.5%
Price: $0.000000^*
Shares after: 259,297
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F1

AXGN transaction

Common Stock

Tax liability

Transaction value
Shares: -2,870
Change %: -1.1%
Price: $32.84^*
Shares after: 256,427
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F2

AXGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,575
Change %: +4.5%
Price: $0.000000^*
Shares after: 268,002
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F1

AXGN transaction

Common Stock

Sale

Transaction value: $171,458
Shares: -5,221
Change %: -1.9%
Price: $32.84
Shares after: 262,781
Date: 16 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: +6,363
Change %
Price: $0.000000^*
Shares after: 6,363
Date: 16 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,363
Exercise price
Footnotes: F3, F4

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: +11,575
Change %
Price: $0.000000^*
Shares after: 11,575
Date: 16 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,575
Exercise price
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.

Footnote F2

This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F4

All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.

Footnote F5

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.